NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

65 % (n=15) had diagnoses of IDH wild type glioblastoma (WHO Grade IV), while 35 % (n=8) of the patients had a diagnosis of IDH mutant malignant glioma (WHO Grade III).

No, you should learn to read and inform yourself better also. They never included IDH mutant patients among their GBM patients.

They are actually excluding them: They say 65% are IDH wild type gioblastoma and 35% IDH mutant malignant glioma (WHO Grade III). In case you don't know 65%+ 35% = 100% and WHO grade III gliomas are not GBM.

Do you even know the difference between GBM and grade III gliomas?

Please don't embarrass yourself more.

And don't put words in my mouth. This trial is very relevant and phase 3 trial is already done and successful.


*Just in case, English is not my native language.